NCT07137585进行中（未招募）1 期
Effects of RO7204239 on Insulin Sensitivity, Muscle Composition and Function in Participants Living With Type 2 Diabetes Mellitus and Overweight or Obesity: A Double-blind, Randomized, Placebo-controlled Study
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Change From Baseline in M-value in a Hyperinsulinemic Euglycemic Glucose Clamp (HEC) at Week 24
研究概览
简要总结
The main purpose of this study is to assess the effect of RO7204239 on insulin sensitivity versus placebo in participants with T2DM and obesity or overweight.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants with T2DM for at least 6 months, treated with diet, exercise and/or metformin alone or in combination with either dipeptidyl peptidase 4 (DPP-4) inhibitor or sodium-glucose co-transporter 2 (SGLT2) at stable dose for the last 3 months prior to study entry and with a HbA1c between ≤ 6.5% and ≤ 10%
- •Body mass index (BMI) within the range of 27.0 to 45.0 kilogram per meter square (kg/m2)
- •Stable body weight for the 3 months prior to screening
- •Participants on lipid-lowering or antihypertensive drugs must be on stable doses for at least 3 months
排除标准
- •Type 1 diabetes mellitus (DM), known latent autoimmune diabetes in adults, or people with an episode of ketoacidosis or hyperosmolar state requiring hospitalisation in 6 months prior to screening
- •Active proliferative diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy requiring acute treatment
- •Uncontrolled comorbid conditions commonly associated with diabetes (for example, hypertension, hyperlipidaemia)
- •Severe hypoglycaemia within 6 months prior to screening visit
- •Current autonomic neuropathy as evidenced by neuropathic urinary retention, resting tachycardia, orthostatic hypotension, or diabetic diarrhea
- •Have evidence of a significant, uncontrolled endocrine abnormality (e.g., thyrotoxicosis and adrenal crises)
- •Are currently taking a central nervous system stimulant (e.g., Ritalin-SR), with the exception of caffeinated beverage
- •Have a known allergy, hypersensitivity, or intolerance to any component of the study treatment (i.e., RO7204239 / placebo) formulation
- •Blood donation of more than 500 milliliters (mL) within the past 3 months or blood transfusion or severe blood loss within 3 months prior to screening
研究组 & 干预措施
RO7204239
Experimental
Participants will receive RO7204239, Q4W, as a SC injection for 24 weeks.
干预措施: RO7204239 (Drug)
Placebo
Experimental
Participants will receive RO7204239 matching placebo, every 4 weeks (Q4W), as a subcutaneous (SC) injection for 24 weeks.
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline in M-value in a Hyperinsulinemic Euglycemic Glucose Clamp (HEC) at Week 24
时间窗: Baseline, Week 24
次要结局
- Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12 and 24(Baseline, Week 12, Week 24)
- Change From Baseline in Glucose Metabolism Assessed Using Fasting Glucose Test at Weeks 12 and 24(Baseline, Week 12, Week 24)
- Change From Baseline in Glucose Metabolism Assessed Using Insulin Test at Weeks 12 and 24(Baseline, Week 12, Week 24)
- Change From Baseline in Glucose Metabolism Assessed Using C-peptide Test at Weeks 12 and 24(Baseline, Week 12, Week 24)
- Change From Baseline in Blood Lipid Profiles at Weeks 12 and 24(Baseline, Week 12, Week 24)
- Change From Baseline in Body Weight at Weeks 12 and 24(Baseline, Week 12, Week 24)
- Change From Baseline in Waist Circumference at Weeks 12 and 24(Baseline, Week 12, Week 24)
- Change From Baseline in Waist to Height Ratio at Weeks 12 and 24(Baseline, Week 12, Week 24)
- Change From Baseline in Total Lean Tissue Volume and Total Adipose Tissue Volume From Abdominal Magnetic Resonance Imaging (MRI) at Weeks 12 and 24(Baseline, Week 12, Week 24)
- Change From Baseline in Muscle Volume From Thigh Muscle MRI at Weeks 12 and 24(Baseline, Week 12, Week 24)
- Change From Baseline in Muscle Fat Infiltration From Thigh Muscle MRI at Weeks 12 and 24(Baseline, Week 12, Week 24)
- Number of Participants With Adverse Events (AEs)(Up to Week 48)
- Number of Participants With Local and Systemic Injection Reactions(Up to Week 48)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Insulin Sensitivity and Substrate Metabolism Before and After Treatment in Patients With Growth Hormone DeficiencyGrowth Hormone DeficiencyNCT00646815University of Aarhus24
已完成
1 期
Effect of LY2189265 on Insulin Secretion in Response to Intravenous GlucoseDiabetes Mellitus, Type 2NCT01300260Eli Lilly and Company32
终止
不适用
Insulin Sensitivity and Metabolism Before and After Treatment in Patients With HypothyroidismHypothyroidismNCT00770016University of Aarhus
已完成
4 期
Impact on insulin sensitivity and insulin resistance after the conversion from tacrolimus twice daily to extended-release tacrolimus once daily in stable renal transplant recipientsinsulin sensitivityinsulin resistanceinsulin sensitivitytacrolimusextended release tacrolimus once dailyinsulin resistanceTCTR20151005001Prajej Ruangkanchanasetr28
终止
不适用
Defining the Role of Insulin Resistance in 'Idiopathic' Dilated CardiomyopathyDilated CardiomyopathyNCT00466713Stanford University